6869N Stock Chart & Stats
$245.66
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$245.66 - $320.77
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$103.30B
Enterprise Value$836.79K
Total Cash (Recent Filing)$84.12B
Total Debt (Recent Filing)$70.48B
Price to Earnings (P/E)26.7
Beta-0.15
Next Earnings
Aug 07, 2026EPS Estimate
1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)56.89
Shares Outstanding629,480,100
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.71
Price to Book (P/B)1.69
Price to Sales (P/S)1.71
P/FCF Ratio20.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLarge and growing equity with historically low leverage provides durable financial flexibility. This strengthens capacity to fund R&D, capital equipment production, and absorb cyclical downturns without forced asset sales, supporting long-term investment in instruments and reagents.
Recurring Consumables & Service RevenueA business model anchored on consumables and multi-year service contracts delivers steady, usage-linked revenue and stickiness. Installed-base-driven reagent pull-through and service contracts create predictable long-term cash flows and high switching costs for customers.
Strong Historical Margins And OCFConsistently healthy gross and net margins historically indicate structural profitability in core diagnostics products. Combined with substantial operating cash flow across years, margins and cash generation underpin the company's ability to reinvest in product development and support stable operations.
Bears Say
2026 Earnings SlowdownA material step-down in revenue and profit in the most recent annual period threatens the engine that fuels instrument placements and reagent demand. If persistent, slower top-line growth reduces recurring sales growth, weakens service contract expansion, and limits reinvestment capacity.
Rising Total DebtAn increase in total debt over recent years erodes some of the company’s conservative financial cushion. Higher leverage reduces optionality for capital allocation, increases interest exposure if rates rise, and narrows the buffer to absorb prolonged earnings weakness or fund strategic initiatives.
Volatile Free Cash FlowIrregular free cash flow and inconsistent cash conversion signal working-capital and investment swings. This variability complicates long-term planning for capex and R&D, may force reliance on external funding in weak years, and undermines predictability of reinvestment from operations.
6869N FAQ
What was Sysmex Corporation’s price range in the past 12 months?
Sysmex Corporation lowest stock price was $245.66 and its highest was $320.77 in the past 12 months.
What is Sysmex Corporation’s market cap?
Sysmex Corporation’s market cap is $103.30B.
When is Sysmex Corporation’s upcoming earnings report date?
Sysmex Corporation’s upcoming earnings report date is Aug 07, 2026 which is in 13 days.
How were Sysmex Corporation’s earnings last quarter?
Sysmex Corporation released its earnings results on May 14, 2026. The company reported $0.304 earnings per share for the quarter, missing the consensus estimate of $0.634 by -$0.331.
Is Sysmex Corporation overvalued?
According to Wall Street analysts Sysmex Corporation’s price is currently Undervalued.
Does Sysmex Corporation pay dividends?
Sysmex Corporation does not currently pay dividends.
What is Sysmex Corporation’s EPS estimate?
Sysmex Corporation’s EPS estimate is 1.01.
How many shares outstanding does Sysmex Corporation have?
Sysmex Corporation has 629,480,100 shares outstanding.
What happened to Sysmex Corporation’s price movement after its last earnings report?
Sysmex Corporation reported an EPS of $0.304 in its last earnings report, missing expectations of $0.634. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sysmex Corporation?
Currently, no hedge funds are holding shares in MX:6869N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sysmex Corporation
Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.